Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04098302 · ClinicalTrials.gov registry record · Phase 2
Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
A Phase 2 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT04098302 is a Phase 2 study that has completed, run by UConn Health. The registered enrollment target is 180 participants.
The verdict
NCT04098302, a Phase 2 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of dutasteride in reducing drinking and heavy drinking in men and women with alcohol use disorder. The investigators hypothesize that dutasteride 1 mg per day will be well tolerated in this patient population and that, compared to placebo treatment, dutasteride will result in a greater reduction in drinks per week and in the frequency of heavy drinking days.
Interventions
- DRUG Placebo Capsules
- DRUG Dutasteride Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04098302
The ClinicalTrials.gov registry entry for NCT04098302 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Capsules is the first listed.
NCT04098302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04098302 about?
NCT04098302 is a clinical study titled "Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy". The purpose of this study is to evaluate the safety and efficacy of dutasteride in reducing drinking and heavy drinking in men and women with alcohol use disorder. The investigators hypothesize that dutasteride 1 mg per day will be well tolerated in this patient population and that, compared to plac...
What is the current status of trial NCT04098302?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2019-10-15. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT04098302?
The interventions under investigation include: Placebo Capsules (DRUG), Dutasteride Capsules (DRUG).
Who is sponsoring clinical trial NCT04098302?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.